# Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

> **NCT04833205** · PHASE2 · UNKNOWN · sponsor: **Hui Bu** · enrollment: 30 (estimated)

## Conditions studied

- Leptomeningeal Metastasis
- Lung Cancer

## Interventions

- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT04833205
- **Lead sponsor:** Hui Bu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-19
- **Primary completion:** 2022-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833205, "Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04833205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*